Company intelligence / Profile preview
TJ Biopharma
Chinatjbio.com ↗
- Ownership
- Public · GTBP
- Development stage
- Other
01
Overview
Uliledlimab has advanced into Phase 2 combination studies with promising early results. Givastomig showed an overall response rate of ~27% and clinical benefit ratio of ~69% at certain doses during Phase I trials. GX-H9 demonstrated non-inferiority to daily somatropin therapy and offers weekly dosing convenience.
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Monoclonal antibodies (mAbs)Long-acting biologics/proteinsBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Sanofi S.A.: Collaboration on uliledlimab development/commercialization in Greater China (€32M upfront/milestones + up to €213M success-based milestones + royalties).Jumpcan Pharmaceutical: Commercialization partner for GX-H9 pediatric growth hormone therapy since at least late2021.Genexine & Handok: Technology partners/co-developers of GX-H9/hyFc platform technology.
Beyond the preview
Go deeper on TJ Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJ Biopharma.